Literature DB >> 2973413

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.

C I Bindon1, G Hale, H Waldmann.   

Abstract

Lysis of human lymphocytes by autologous complement had been studied using a range of monoclonal antibodies against different antigens. Antigen specificity (and not antibody isotype) was the most important factor which influenced cell lysis and this could not be accounted for merely by differences in surface density between antigens. Three antigens with comparable surface density were studied in detail: CAMPATH-1 (lytic), major histocompatibility complex class I (lytic) and leukocyte common antigen (poorly lytic). C1q binding was roughly proportional to antibody binding and dependent on antibody isotype. However, the lytic antibodies were much better able to bind and activate whole C1 than the poorly lytic ones. This result would not have been predicted from traditional concepts of complement activation but can be interpreted in the light of models for C1 activation which involve Fc-Fc interactions, Fc-C1r2s2 interactions and a critical C1q stem-arm angle for C1 binding and activation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2973413     DOI: 10.1002/eji.1830181006

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  24 in total

1.  Complement component C1q enhances the biological activity of influenza virus hemagglutinin-specific antibodies depending on their fine antigen specificity and heavy-chain isotype.

Authors:  Jing Qi Feng; Krystyna Mozdzanowska; Walter Gerhard
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

Review 2.  Experimental membranous nephropathy redux.

Authors:  Andrey V Cybulsky; Richard J Quigg; David J Salant
Journal:  Am J Physiol Renal Physiol       Date:  2005-10

3.  Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Authors:  Kirstie L S Cleary; H T Claude Chan; Sonja James; Martin J Glennie; Mark S Cragg
Journal:  J Immunol       Date:  2017-04-12       Impact factor: 5.422

4.  Effector function activities of a panel of mutants of a broadly neutralizing antibody against human immunodeficiency virus type 1.

Authors:  M Hezareh; A J Hessell; R C Jensen; J G van de Winkel; P W Parren
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Variable CD52 expression in mature T cell and NK cell malignancies: implications for alemtuzumab therapy.

Authors:  Liuyan Jiang; Constance M Yuan; Julia Hubacheck; John E Janik; Wyndham Wilson; John C Morris; Gregory A Jasper; Maryalice Stetler-Stevenson
Journal:  Br J Haematol       Date:  2009-02-19       Impact factor: 6.998

6.  Cross-linking of the CAMPATH-1 antigen (CD52) mediates growth inhibition in human B- and T-lymphoma cell lines, and subsequent emergence of CD52-deficient cells.

Authors:  W Rowan; J Tite; P Topley; S J Brett
Journal:  Immunology       Date:  1998-11       Impact factor: 7.397

7.  Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.

Authors:  M Q Xia; G Hale; M R Lifely; M A Ferguson; D Campbell; L Packman; H Waldmann
Journal:  Biochem J       Date:  1993-08-01       Impact factor: 3.857

Review 8.  Antibody engineering to develop new antirheumatic therapies.

Authors:  John D Isaacs
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

9.  Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease.

Authors:  J D Isaacs; N Burrows; M Wing; M T Keogan; P R Rebello; R A Watts; R J Pye; P Norris; B L Hazelman; G Hale; H Waldmann
Journal:  Clin Exp Immunol       Date:  1997-11       Impact factor: 4.330

10.  A partner monoclonal antibody to Moab 730 kills 100% of DU145 and PC3 androgen-independent cancer cells.

Authors:  Hemant Kumar Vyas; Rahul Pal; Nirmal K Lohiya; G P Talwar
Journal:  J Biosci       Date:  2009-12       Impact factor: 1.826

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.